SEARCH:   Advanced

Blood, 15 January 2008, Vol. 111, No. 2, pp. 558-565. Prepublished online as a Blood First Edition Paper on October 25, 2007; DOI 10.1182/blood-2007-06-095331. This Article Full Text (PDF) Supplemental Appendix Erratum (v111,p5761) All Versions of this Article: blood-2007-06-095331v1 111/2/558    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Hoster, E. Articles by Unterhalt, M. Search for Related Content PubMed PubMed Citation Articles by Hoster, E. Articles by Unterhalt, M. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted June 18, 2007 Accepted September 27, 2007 A new prognostic index (MIPI) for patients with advanced stage mantle cell lymphoma Eva Hoster, Martin Dreyling, Wolfram Klapper, Christian Gisselbrecht, Achiel van Hoof, Hanneke C Kluin-Nelemans, Michael Pfreundschuh, Marcel Reiser, Bernd Metzner, Hermann Einsele, Norma Peter, Wolfram Jung, Bernhard Wormann, Wolf-Dieter Ludwig, Ulrich Duhrsen, Hartmut Eimermacher, Hannes Wandt, Joerg Hasford, Wolfgang Hiddemann, and Michael Unterhalt* Department of Internal Medicine III, University of Munich, Munich, Germany Institute of Pathology, Lymph Node Registry, University of Kiel, Kiel, Germany Department of Hematology, Hopital Saint Louis, Paris, France Department of Hematology, Akademisch Ziekenhuis St-Jan, Brugge, Belgium Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands Department of Internal Medicine I, Saarland University Medical School, Homburg, Germany Department of Internal Medicine I, University of Cologne, Cologne, Germany Department of Oncology and Hematology, Klinikum Oldenburg, Oldenburg, Germany Department of Internal Medicine I, University of Wurzburg, Wurzburg, Germany Department of Hematology/Oncology, Carl-Thiem Hospital, Cottbus, Germany Department of Hematology and Oncology, University of Gottingen, Gottingen, Germany Medizinische Klinik, Stadtisches Klinikum Braunschweig, Braunschweig, Germany Department of Hematology and Oncology, Helios Klinikum Berlin-Buch, Berlin, Germany Department of Hematology, University Hospital Essen, Essen, Germany Department of Hematology and Oncology, Katholisches Krankenhaus Hagen, Hagen, Germany Medical Department 5, Klinikum Nurnberg, Nurnberg, Germany Institute of Medical Informatics, Biometry and Epidemiology, University of Munich, Munich, Germany * Corresponding author; email: michael.unterhalt{at}med.uni-muenchen.de. Background: There is no generally established prognostic index for patients with mantle cell lymphoma (MCL), as International Prognostic Index (IPI) and Follicular Lymphoma International Prognostic Index (FLIPI) have been developed for diffuse large cell and follicular lymphoma patients, respectively. Methods: Using data of 455 advanced stage MCL patients treated within three clinical trials we examined the prognostic relevance of IPI and FLIPI and derived a new prognostic index (MCL international prognostic index, MIPI) of overall survival (OS). Statistical methods included Kaplan-Meier estimates and logrank test for evaluating IPI and FLIPI and multiple Cox regression for developing the MIPI. Results: IPI and FLIPI showed poor separation of survival curves. According to the MIPI, patients were classified into low risk (44% of patients, median OS not reached), intermediate risk (35%, 51 months), and high risk groups (21%, 29 months), based on the four independent prognostic factors age, ECOG performance status, LDH and leukocyte count. Cell proliferation (Ki-67) was exploratively analyzed as important biological marker and showed strong additional prognostic relevance. Discussion: The MIPI is the first prognostic index particularly suited for MCL patients and may serve as important tool to facilitate risk-adapted treatment decisions in patients with advanced stage MCL. This study is registered at http://clinicaltrials.gov as NCT00016887. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: O. Determann, E. Hoster, G. Ott, H. Wolfram Bernd, C. Loddenkemper, M. Leo Hansmann, T. E. F. Barth, M. Unterhalt, W. Hiddemann, M. Dreyling, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group Blood, February 15, 2008; 111(4): 2385 - 2387. [Abstract] [Full Text] [PDF] B. S. Kahl New Therapeutic Strategies for Mantle Cell Lymphoma ASCO Educational Book, January 1, 2008; 2008(1): 392 - 397. [Abstract] [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020